Identification | Back Directory | [Name]
Vonoprazan Fumarate impurity | [CAS]
1885094-62-1 | [Synonyms]
Vonoprazan-19 Vonoprazan-014 Vonoprazan Impurity U9 Vonoprazan Impuirty U6 Vonoprazan Impurity 67 TAK438 Impurity 9 Monomer Vonoprazan Fumarate impurity Vonoprazan Impurity 9 Monomer N,N-Dimethylmethanamine Vonoprazan 5-(3-fluorophenyl)-1H-pyrrole-3-carbonitrile 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-... (5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methanol (5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methanamine 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carboxylic acid 1H-Pyrrole-3-methanamine, 5-(2-fluorophenyl)-N,N-dimethyl-1-(3-pyridinylsulfonyl)- 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N,N-dimethylmethanamine N-((5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methyl)-N-methylaspartic acid N-((5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methyl)-N-methylhydroxylamine 1-(1-((1,6-dihydropyridin-3-yl)sulfonyl)-5-(2-fluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine 5-((2-(2-fluorophenyl)-4-((methylamino)methyl)-1H-pyrrol-1-yl)sulfonyl)-1,2,3,4-tetrahydropyridin-2-ol 1-(5-(2-fluorophenyl)-1H-pyrrol-3-yl)-N-((5-(2-fluorophenyl)-1H-pyrrol-3-yl)methyl)-N-methylmethanamine Vonoprazan impurity 17/1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N,N- dimethylmethanamine 1-(5-(2-fluorophenyl)-1-((1,4,5,6-tetrahydropyridin-3-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-((5-(2-fluorophenyl)-1H-pyrrol-3-yl)methyl)-N-methylmethanamine 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-((5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methyl)-N-methylmethanamine | [Molecular Formula]
C18H18FN3O2S | [MDL Number]
MFCD34472183 | [MOL File]
1885094-62-1.mol | [Molecular Weight]
359.42 |
Hazard Information | Back Directory | [Uses]
N,N-Dimethylmethanamine Vonoprazan is an impurity of Vonoprazan a novel potassium-?competitive acid blocker for the treatment of acid-?related diseases. |
|
|